The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia

FMS-like tyrosine kinase 3–targeted (FLT3-targeted) therapies have shown initial promise for the treatment of acute myeloid leukemia (AML) expressing FLT3-activating mutations; however, resistance emerges rapidly. Furthermore, limited options exist for the treatment of FLT3-independent AML, demonstr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCI Insight
Main Authors: Minson, Katherine A., Smith, Catherine C., DeRyckere, Deborah, Libbrecht, Clara, Lee-Sherick, Alisa B., Huey, Madeline G., Lasater, Elisabeth A., Kirkpatrick, Gregory D., Stashko, Michael A., Zhang, Weihe, Jordan, Craig T., Kireev, Dmitri, Wang, Xiaodong, Frye, Stephen V., Earp, H. Shelton, Shah, Neil P., Graham, Douglas K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2016
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4855528/
https://ncbi.nlm.nih.gov/pubmed/27158668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.85630
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados